Top Biotechnology Stock Picking: Eleven Biotherapeutics, Inc. (EBIO), Esperion Therapeutics, Inc. (ESPR) – The Independent Republic

Eleven Biotherapeutics, Inc. (EBIO) ended last trading session with a change of 3.08 percent. It trades at an average volume of 1.15M shares versus 1.16M shares recorded at the end of last trading session. The share price of $2.34 is at a distance of 832.27 percent from its 52-week low and down -60.8 percent versus its peak. The company has a market cap of $54.22M and currently has 23.17M shares outstanding. The share price is currently 8.53 percent versus its SMA20, 8.29 percent versus its SMA50, and -6.67 percent versus its SMA200. The stock has a weekly performance of 11.96 percent and is 22.51 percent year-to-date as of the recent close.

On November 14, 2016 Eleven Biotherapeutics, Inc. (EBIO) reported financial results for the third quarter ended September 30, 2016, and recent business highlights.

This is an exciting period for Eleven. We completed the Roche licensing deal, including $30 million in upfront and milestone payments received to date. We also completed the acquisition of Viventia Bio Inc. which allowed us to become a late-stage oncology company. Perhaps most excitingly, we are making significant progress in moving forward what we believe could be therapeutics that materially improve patients lives. We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018, said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead.

Esperion Therapeutics, Inc. (ESPR) recently recorded 7.42 percent change and currently at $17.66 is 87.87 percent away from its 52-week low and down -12.53 percent versus its peak. It has a past 5-day performance of 59.53 percent and trades at an average volume of 290.88K shares. The stock has a 1-month performance of 29.76 percent and is 41.05 percent year-to-date as of the recent close. There were about 17.45M shares outstanding which made its market cap $308.17M. The share price is currently 43.42 percent versus its SMA20, 44.08 percent versus its SMA50, and 37.75 percent versus its SMA200.

On Jan. 25, 2017 Esperion Therapeutics, Inc. (ESPR) announced completion of patient enrollment in the global pivotal Phase 3 long-term safety and tolerability study of bempedoic acid. Enrollment of this study was completed ahead of schedule in approximately 2,000 patients treated with bempedoic acid or placebo at high cardiovascular disease (CVD) risk with hypercholesterolemia whose LDL-C is not adequately controlled with current lipid-modifying therapies. Top-line results from this study are expected by Q2 2018.

Link:
Top Biotechnology Stock Picking: Eleven Biotherapeutics, Inc. (EBIO), Esperion Therapeutics, Inc. (ESPR) - The Independent Republic

Related Posts

Comments are closed.